Rosuvastatin was found to be more beneficial than placebo at reducing cardiovascular morbidity and mortality, claim US researchers.
The JUPITER study began in 2003 and involved over 15,000 patients, aged at least 50, who had no history of MI, stroke or arterial revascularisation and LDL cholesterol levels below 120mg/dL. They were randomly assigned to receive either 20mg rosuvastatin daily or placebo.
But last week, the study was halted because it had become clear that participants given placebo had an increased risk of CVD events and death.
Berkshire GP Dr George Kassianos, a member of the British Cardiology Society, said: ‘This is an excellent outcome study for the use of rosuvastatin. It is much more difficult to show outcomes in primary than secondary prevention.'
Results of the JUPITER trial are yet to be published.
Comment below and tell us what you think